- 作者: Ai-Sheng Ho; Chun-Chia Cheng; Shui-Cheng Lee; Meng-Lun Liu; Jing-Ying Lee; Wen-Ming Wang; Chia-Chi Wang
- 作者服務機構: Division of Gastroenterology, Cheng Hsin General Hospital, Taipei, Taiwan, R.O.C.
- 中文摘要: --
- 英文摘要:
Background: The gold standard of assessing liver fibrosis is liver biopsy, which is invasive and not
without risk. Therefore, searching for noninvasive serologic biomarkers for liver
fibrosis is an importantly clinical issue.
Methods: A total of 16 healthy volunteers and 45 patients with chronic hepatitis C virus (HCV)
were enrolled (F0: n=16, F1: n=7, F2: n=17, F3: n=8 and F4: n=13, according to the
METAVIR classification). Three serum samples of each fibrotic stage were analyzed by
two-dimension difference gel electrophoresis (2D-DIGE). The differential proteins were
identified by the cooperation of MALDI-TOF/TOF and MASCOT; then western
blotting and Bio-Plex Suspension Array were used to quantify the protein levels.
Results: Three prominent candidate biomarkers were identified: alpha 2 macroglobulin (A2M) is
up regulated; vitamin D binding protein (VDBP) and apolipoprotein AI (ApoAI) are
down regulated. The serum concentration of A2M was significantly different among
normal, mild (F1/F2) and advanced fibrosis (F3/F4) (p < 0.01). The protein levels of
VDBP and ApoAI were significantly higher in normal/mild fibrosis, when compared to those in advanced fibrosis (both p < 0.01).
Conclusions : This study not only reveals three putative biomarkers of liver fibrosis (A2M, VDBP and
ApoAI) but also proves the differential expressions of those markers in different stages
of fibrosis. We expect that combination of these novel biomarkers could be applied
clinically to predict the stage of liver fibrosis without the need of liver biopsy. - 中文關鍵字: --
- 英文關鍵字: --